Funda Meric-Bernstam
MD
Chair, Department of Investigational Cancer Therapeutics
👥Biography 个人简介
Funda Meric-Bernstam leads one of the largest phase 1 programs in the world, with extensive work on antibody drug conjugates targeting HER2, HER3, TROP2, and other lineage antigens. Her work helped establish ADCs in tumor agnostic and uncommon indications. She drives biomarker informed ADC development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Funda Meric-Bernstam 的研究动态
Follow Funda Meric-Bernstam's research updates
留下邮箱，当我们发布与 Funda Meric-Bernstam（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment